OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Marta Barrachina

2 Projects | 1 Researchers | $2,397,652 Invested

2023

ADmit Therapeutics S.L.

Marta Barrachina, PhD, MBA

MAP-AD, a revolutionary Methylation Profiling approach for early diagnosis of Alzheimer’s Disease

  • Funding Amount: $1,900,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2019

ADmit Therapeutics S.L.

Marta Barrachina, PhD, MBA

ADmit Test: a new kit for an early Alzheimer's disease detection

  • Funding Amount: $497,652
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Mitochondria/Metabolic Function
  • Status: Closed